Drug Trial News

RSS

Mirati announces initiation of glesatinib Phase 2 clinical trial in NSCLC patients

Mirati Therapeutics, Inc. today announced that the Phase 2 clinical trial of glesatinib (MGCD265) has commenced. The Company also announced that "glesatinib" is the proposed generic name for MGCD265.

21 Dec 2015

SciClone plans to pursue development of SGX942 in the Greater China market

SciClone Pharmaceuticals, Inc. today announced plans to pursue development and registration of SGX942 in the Greater China market, for the treatment of oral mucositis.

21 Dec 2015

Regulus begins RG-125(AZD4076) Phase I study for treatment of NASH in patients with type 2 diabetes/pre-diabetes

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that dosing has begun in a first-in-human Phase I clinical study of RG-125(AZD4076), by its collaboration partner AstraZeneca.

21 Dec 2015

GeNeuro initiates GNbAC1 Phase IIb study in Relapsing-Remitting Multiple Sclerosis

GeNeuro SA, a pioneer of new therapies for neurology and autoimmune disorders, announced today that it has initiated its planned Phase IIb study “CHANGE-MS” (Clinical trial assessing the HERV-W Env ANtagonist GNbAC1 for Efficacy in Multiple Sclerosis) with its lead antibody GNbAC1 in Relapsing-Remitting Multiple Sclerosis (RRMS).

21 Dec 2015

Adaptimmune begins Phase I/II study of affinity enhanced T-cell therapy targeting MAGE-A10 in NSCLC patients

Adaptimmune Therapeutics plc, a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that it has initiated a Phase I/II study of its affinity enhanced T-cell therapy targeting the MAGE-A10 cancer antigen in patients with locally advanced or metastatic (Stage IIIb or IV) non-small cell lung cancer (NSCLC), the most prevalent type of lung cancer representing approximately 85 percent of lung cancers.

21 Dec 2015

Combination therapy can help overcome endocrine resistance in women with advanced breast cancer

Data collected in Japanese and Korean patients included in the global PALOMA3 trial provides evidence that combining palbociclib with fulvestrant is an effective strategy to overcome endocrine resistance in women with hormone receptor positive (HR+), HER2 negative (HER2-) advanced breast cancer.

20 Dec 2015

DS Biopharma reports completion of DS102 Phase I trial for treatment of fatty liver disorders

DS Biopharma, a privately held biopharmaceutical company, today announced the successful completion of a Phase I trial with an oral formulation of the active pharmaceutical ingredient DS102 (15-HEPE) which is being explored for the treatment of fatty liver disorders, such as non-alcoholic steatohepatitis (NASH) and pulmonary disorders, such as idiopathic pulmonary fibrosis (IPF).

18 Dec 2015

Kitov announces more data from Phase III trial on the favorable blood pressure effects of KIT-302

Kitov Pharmaceuticals, an innovative biopharmaceutical company focused on late-stage drug development, today announced more data from its successfully concluded Phase III trial for its lead drug candidate, KIT-302. Data showed the favorable blood pressure effects of KIT-302 were present in all blood pressure variables measured in the study.

18 Dec 2015

Chi-Med announces initiation of Phase III sulfatinib registration trial in patients with NETs in China

Hutchison China MediTech Limited today announces that Hutchison MediPharma Limited, its drug R&D subsidiary, has initiated SANET-ep, a Phase III sulfatinib (HMPL-012) registration trial in China in patients with extra-pancreatic neuroendocrine tumors ("NETs"), which are all non-pancreatic NETs, including, for example, NETs originating in the lymph, lung and across the gastrointestinal tract.

18 Dec 2015

Novel strategies on the way for difficult-to-treat head and neck cancer

Novel strategies are on the way for difficult-to-treat and advanced head and neck cancer, the most heterogeneous group of malignancies which are generally associated with poor survival, and encouraging results have been presented at the first ESMO Asia 2015 Congress in Singapore.

17 Dec 2015

Soligenix reports positive results from SGX942 Phase 2 trial in patients with head and neck cancer

Soligenix, Inc., a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today positive results in its Phase 2 clinical trial, in which SGX942, a first-in-class Innate Defense Regulator (IDR), at a dose of 1.5 mg/kg, successfully reduced the median duration of severe oral mucositis by 50% in all patients and by 67% in patients receiving the most aggressive chemoradiation therapy (CRT) for treatment of their head and neck cancer.

16 Dec 2015

Array BioPharma reports top-line results from binimetinib Phase 3 trial in patients with NRAS-mutant melanoma

Array BioPharma today reported top-line results from the ongoing Phase 3 clinical trial of binimetinib in patients with advanced NRAS-mutant melanoma, known as the NEMO trial. The study met its primary endpoint of improving progression-free survival (PFS) compared with dacarbazine treatment.

16 Dec 2015

Researchers test new concept in type 2 diabetes patients going into remission

Remission is well-known as the goal in cancer treatment but scientists are discovering it's also an exciting possibility for those with type 2 diabetes.

16 Dec 2015

Kitov Pharmaceuticals' KIT-302 drug candidate meets primary efficacy endpoint in Phase III clinical trial

Kitov Pharmaceuticals, an innovative biopharmaceutical company focused on late-stage drug development, announced today that the Phase III, double-blind, placebo-controlled clinical trial for its leading drug candidate, KIT-302, successfully met the primary efficacy endpoint of the trial protocol as approved by the U.S. Food & Drug Administration (FDA).

15 Dec 2015

Lupuzor may become first non-immunosuppressant therapy for lupus

Lupuzor may become the first specific and non-immunosuppressant therapy for lupus, a disabling autoimmune disease that is currently incurable.

15 Dec 2015

ImmunoCellular partners with CBTC for ICT-107 phase 3 registrational trial in patients with glioblastoma

ImmunoCellular Therapeutics, Ltd. today announced the establishment of an agreement with a major Canadian cancer cooperative group, The Canadian Brain Tumour Consortium, for the phase 3 registrational trial of its cancer immunotherapy ICT-107 in patients with newly diagnosed glioblastoma.

14 Dec 2015

Innovative Phase II trial evaluates effectiveness of diabetes medication for lymphoma

Cancer, it could be said, grows like a weed: rapidly, invasively, and with devastating impact on the place it infests. Also like a weed, cancer can't grow on its own — it needs nourishment, which it drains from the human body, just as weeds take nutrients in the soil away from other plants.

13 Dec 2015

Combination treatment provides effective one-two punch against prostate cancer

Results from a long-term clinical trial conducted by cancer researchers at Houston Methodist Hospital show that combining radiation treatment with "suicide gene therapy," a technique in which prostate cancer cells are genetically modified so they signal a patient's immune system to attack them, provides a safe and effective one-two punch against the disease.

12 Dec 2015

NIAID scientists successfully test prime-boost H7N9 influenza vaccine concept in clinical trial

In clinical trials, several candidate H7N9 pandemic influenza vaccines made from inactivated viruses have been shown to be safe and to generate an immune response. However, scientists believe for practical use, these potential vaccines would require multiple doses or the addition of adjuvants, which enhance the immune response.

12 Dec 2015

Anastrozole drug effective in treating early form of breast cancer

The drug anastrozole is effective in treating an early form of breast cancer, according to a clinical trial led by Queen Mary University of London. The results of the IBIS-II DCIS trial show that anastrozole is as effective as tamoxifen for this type of breast cancer and could offer a new treatment option for post-menopausal women.

12 Dec 2015

Drug Trial News

Mirati announces initiation of glesatinib Phase 2 clinical trial in NSCLC patients

SciClone plans to pursue development of SGX942 in the Greater China market

Regulus begins RG-125(AZD4076) Phase I study for treatment of NASH in patients with type 2 diabetes/pre-diabetes

GeNeuro initiates GNbAC1 Phase IIb study in Relapsing-Remitting Multiple Sclerosis

Adaptimmune begins Phase I/II study of affinity enhanced T-cell therapy targeting MAGE-A10 in NSCLC patients

Combination therapy can help overcome endocrine resistance in women with advanced breast cancer

DS Biopharma reports completion of DS102 Phase I trial for treatment of fatty liver disorders

Kitov announces more data from Phase III trial on the favorable blood pressure effects of KIT-302

Chi-Med announces initiation of Phase III sulfatinib registration trial in patients with NETs in China

Novel strategies on the way for difficult-to-treat head and neck cancer

Soligenix reports positive results from SGX942 Phase 2 trial in patients with head and neck cancer

Array BioPharma reports top-line results from binimetinib Phase 3 trial in patients with NRAS-mutant melanoma

Researchers test new concept in type 2 diabetes patients going into remission

Kitov Pharmaceuticals' KIT-302 drug candidate meets primary efficacy endpoint in Phase III clinical trial

Lupuzor may become first non-immunosuppressant therapy for lupus

ImmunoCellular partners with CBTC for ICT-107 phase 3 registrational trial in patients with glioblastoma

Innovative Phase II trial evaluates effectiveness of diabetes medication for lymphoma

Combination treatment provides effective one-two punch against prostate cancer

NIAID scientists successfully test prime-boost H7N9 influenza vaccine concept in clinical trial

Anastrozole drug effective in treating early form of breast cancer

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Latest News